In 2019, approximately 40% of oncology patients in the United States were eligible for treatment with immune checkpoint inhibitors (ICIs). Furthermore, it is estimated that one in seven patients who ...
A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, neurology, hematology, emergency medicine ...
The preeminent guidelines for the diagnosis and management of hypoparathyroidism (hypoPT) are the 2022 Evaluation and Management Guidelines, developed by the Second International Workshop on hypoPT.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results